MedTrace Logo

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

NCT00559715 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2009-03-26

No results posted yet for this study

Summary

The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatment of AMD in comparison to the related fragment ranibizumab.

Conditions

  • Age-Related Neovascular Macular Degeneration

Interventions

DRUG

bevacizumab

1.25 mg intravitreally monthly/on demand

DRUG

ranibizumab

0.5 mg intravitreally monthly/on demand

Sponsors & Collaborators

  • Kompetenzzentrum für Klinische Studien, Bremen

    collaborator UNKNOWN

  • Klinikum Bremen-Mitte, gGmbH

    lead OTHER

Principal Investigators

  • Bernd Muehlbauer, Professor MD · Department of Pharmacology, Klinikum Bremen Mitte, Bremen, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-08-31
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559715 on ClinicalTrials.gov